The TWiVers review phase 3 efficacy and safety results for the Novavax COVID-19 vaccine, effects on the neonatal immune system caused by maternal infection with SARS-CoV-2, and NHC, the metabolite of molnupiravir, causes mutations in cellular DNA.
In COVID-19 clinical update #84, Dr. Griffin discusses childrens’ antibody response to vaccination, phase 3 results of Novavax vaccine, heterologous vaccination, antithrombotic therapy, EUA for molnupiravir, phase 3 results of AZD7442, serum ferritin levels and outcomes, heparin therapy, and WHO strategy for global vaccination.
David Tuller returns to TWiV to revisit his work to expose the methodological and ethical problems with the PACE trial, and the post-acute sequelae to SARS-CoV-2 infection, also known as long COVID.
Moshe and Ivet join TWiV to discuss their finding that MIS-C is a consequence of a superantigen in the spike protein of SARS-CoV-2 that causes activation of a skewed population of T cell receptor bearing lymphocytes, leading to hyperinflammation.
In COVID-19 clinical update #83, Daniel Griffin discusses upcoming FDA discussions on vaccines, strategies to prevent transmission at youth camps, outbreaks at summer camps, impact of vaccination on transmission, AZD7442 request for EUA filed, EUA issued for home antigen test, phase 3 data on AZD1222 vaccine, 6 month effectiveness of Pfizer/BioNTech vaccine, estimates of durability of immunity against reinfection, Molnupiravir interim results, optimal time for monoclonal antibody infusion, IVIG plus Infliximab for MIS-C, and effect of vaccination on long COVID.
From the 2021 online meeting of the European Society for Clinical Virology, Vincent speaks with meeting speakers on COVID-19 vaccines, immunity, how countries responded to the pandemic, and how to prepare for the next one.
TWiV considers lessons learned from COVID-19 about emergency drug use during a pandemic, and selection of AAV capsids to produce vectors that efficiently deliver genes to muscle cells.
In COVID-19 clinical update #82, Daniel Griffin reviews vaccines for 5-12 years old, safety of a third vaccine dose, Oklahoma reinfection data, Regencov outcomes, Pfizer protease inhibitor, impact of Tocilizumab, and incidence of long COVID.
TWiV reveals isolation from bats in Laos of a SARS-CoV-2 like virus with a spike protein that allows entry into human cells, and exploration of a herpesvirus vector for immunization of vampire bats against rabies virus.
In COVID-19 clinical update #81, Daniel Griffin discusses vaccine boosters, vaccination during pregnancy, mRNA vaccine comparison, J&J vaccine booster, EUA expansion for Lilly monoclonals, remdesivir reduces risk of hospitalization, and anticoagulation regimens.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Brianne Barker, Ph.D.
Rich Condit, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Angela Mingarelli, DVM
Jolene Ramsey, Ph.D.
Kathy Spindler, Ph.D.